Aclaris Therapeutics (NASDAQ:ACRS) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01), Zacks reports. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Aclaris Therapeutics Stock Down 7.2 %

Shares of ACRS traded down $0.15 on Thursday, hitting $1.95. The company’s stock had a trading volume of 638,470 shares, compared to its average volume of 769,210. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The firm’s fifty day moving average price is $2.47 and its 200-day moving average price is $2.15. The firm has a market capitalization of $139.15 million, a price-to-earnings ratio of -3.75 and a beta of 0.50.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $3.00 to $13.00 in a research report on Monday, November 18th. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald raised shares of Aclaris Therapeutics to a “strong-buy” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.